PARP1 and anemia (phenotype): The treatment regimen comprising both a PARP inhibitor and platinum showed a higher risk of anemia, leukopenia, diarrhea, and alopecia, compared to PARP inhibitors without platinum; the safety profile to platinum-based chemotherapy was comparable to PARP inhibitor plus platinum.